Erythromycin as a prokinetic agent in infants and children

Curry, Joseph I.; Lander, T. D.; Stringer, Mark D.

doi:10.1046/j.1365-2036.2001.00964.x

Cited by 61 publications

(35 citation statements)

References 58 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Efeitos gástricos pró-cinéticos da eritromicina foram reconhecidos nos últimos 20 anos 62 . Estudos demonstram que a eritromicina exerce seus efeitos motores gastrintestinais via ativação direta dos receptores da motilina.…”

Section: Situação Clínica Tratamentounclassified

“…No esôfago, a eritromicina parece aumentar a pressão do esfíncter esofágico inferior em jejum e pós-alimentação e a amplitude das contrações esofágicas na porção mais distal do órgão. Esses efeitos já foram observados em pacientes com DRGE 62 , indicando que a droga possa ter emprego clínico nesses pacientes 63 . Contudo, foi identificada uma associação entre eritromicina e desenvolvimento de estenose hipertrófica do piloro em lactentes 64 .…”

Section: Situação Clínica Tratamentounclassified

“…A dose oral de eritromicina recomendada para estimular a motilidade gástrica é muito inferior à dose antibiótica, tendo sido recomendada uma dose de 1-3 mg/kg. A dose para tratamento da DRGE não é conhecida 62 .…”

Section: Situação Clínica Tratamentounclassified

See 2 more Smart Citations

Treatment of gastroesophageal reflux disease

Guimarães¹,

Marguet²,

Camargos³

2006

J Pediatr (Rio J)

View full text Add to dashboard Cite

Objective: To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects. To identify particularities of pharmacological treatment of esophageal and extraesophageal manifestations of the disease.Sources: Electronic search of the PubMed/MEDLINE and Cochrane Collaboration databases. Controlled and randomized studies published since 2000 and reviews representing consensus positions and directives published within the last 10 years were identified. Summary of the findings:The drugs currently available for the treatment of GERD do not act in the primary mechanism of the disease, i.e., transitory relaxation of the lower esophageal sphincter. Pharmacological treatment of GERD with symptoms or with esophageal injury is based on the suppression of acid secretion, particularly with proton pump inhibitors. When the hyperreactivity of the lower airways coexists with esophageal GERD symptoms, suppression of acid secretions should be of benefit in managing the respiratory disease in the presence of a causal relationship; however, this is not usual. When esophageal symptoms are not present, esophageal 24-hour pH study should be carried out prior to starting pharmacological treatment for GERD. Improvement of respiratory symptoms may be delayed with relation to esophageal symptoms. It is common for GERD to recur and pharmacological treatment should be repeated or continued indefinitely, depending on clinical presentation of the disease. Conclusions:The strategies that have been proposed for the pharmacological treatment of GERD in children are primarily based on studies of case series or on studies with adults. There have been very few controlled and randomized studies in children. Undertaking a greater number of these studies might reinforce existing aspects or establish new aspects of management.J Pediatr (Rio J). 2006;82(5 Suppl):S133-45: Gastroesophageal reflux, child, drug therapy, esophagitis, respiratory tract diseases, asthma. ResumoObjetivo: Rever a literatura sobre tratamento da doença do refluxo gastroesofágico (DRGE) com ênfase nos aspectos farmacológi-cos. Identificar particularidades do tratamento farmacológico nas manifestações esofágicas e extra-esofágicas da doença.Fontes de dados: Busca eletrônica na base de dados PubMed/ MEDLINE e Cochrane Collaboration. Procurou-se identificar estudos controlados e randomizados publicados a partir de 2000, bem como revisões que representassem consensos e diretrizes publicados nos últimos 10 anos.Síntese dos dados: Nenhuma das drogas atualmente usadas no tratamento da DRGE altera comprovadamente o mecanismo principal da doença, ou seja, os relaxamentos transitórios do esfíncter esofágico inferior. O tratamento farmacológico da DRGE com sintomas ou com lesões esofágicas é baseado na inibição da secreção ácida, em particular pelos inibidores da bomba de prótons (IBP). Nas situações em que a hiper-reatividade das vias aéreas inferiores coexiste com sintomas esofágicos da DRGE, a inibição da secreção ácida deve...

show abstract

Section: Situação Clínica Tratamentounclassified

See 1 more Smart Citation

Treatment of gastroesophageal reflux disease

Guimarães¹,

Marguet²,

Camargos³

2006

J Pediatr (Rio J)

View full text Add to dashboard Cite

show abstract

“…The same drug in the dose of <12 mg/ kg /day q 6-8 hours, shortens the gastric emptying time and whole gut transit time in infants [4,5]. Erythromycin appears to be equally effective when given orally (ethyl succinate, stearate or estolate) or intravenously (lactobionate) [6].…”

Section: Introductionmentioning

confidence: 99%

Effect of Erythromycin on Gastric Emptying Time of Low Birth Weight Babies

Mathai

Bawa

Bhandari³

2007

Medical Journal Armed Forces India

View full text Add to dashboard Cite

Background: To study the promotility effects of low dose erythromycin on gastric emptying time in a population of normal low birth weight (LBW) neonates on breast feeds with or without nutritional supplements and human milk fortifier (HMF). Method: A randomised control trial involving 50 neonates was undertaken and they were given 6mg/kg/day of oral erythromycin or placebo in three divided doses for four consecutive days in the first two weeks of life. The gastric emptying time (GET) was assessed ultrasonographically by measuring the decrease in the antral cross sectional area (ACSA). The time taken for the ACSA to become half the prefeed value, was taken as t/2 or half GET. The babies were also assessed for pre and post intervention side effects of the drug. The results were analysed using SPSS ver 11.5. Results: The test group showed a significant decrease in GET after the intervention. This effect was mainly seen in the preterm babies as compared to term Small for Gestational Age (SGA) babies. The decrease in GET was more in babies born after 34 weeks of gestation as compared to smaller babies. The reduction in GET was seen in babies on breast milk alone and nutritional supplements with breast milk but not when HMF was added. No side effects of the drug were noted. Conclusion: Low dose erythromycin is a safe way of decreasing gastric emptying in preterm babies born after 34 weeks of gestation in the first two weeks of life. MJAFI 2007; 63 : 226-228

show abstract

“…The dosage for the treatment of GERD is not known. 62 Baclofen is a gamma-aminobutyric acid agonist (GABA B) which, despite not being a prokinetic drug, has been shown to inhibit lower esophageal sphincter relaxation in studies with animals and humans. It is expected that, due to its active mechanism, this drug can interfere with Cimetidine inhibits CYP and, for this reason, can increase the levels of several drugs that are metabolized by these enzymes.…”

Section: Prokineticsmentioning

confidence: 99%

Tratamento da doença do refluxo gastroesofágico

Guimarães

Marguet

Camargos

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objective: To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects. To identify particularities of pharmacological treatment of esophageal and extraesophageal manifestations of the disease.Sources: Electronic search of the PubMed/MEDLINE and Cochrane Collaboration databases. Controlled and randomized studies published since 2000 and reviews representing consensus positions and directives published within the last 10 years were identified. Summary of the findings:The drugs currently available for the treatment of GERD do not act in the primary mechanism of the disease, i.e., transitory relaxation of the lower esophageal sphincter. Pharmacological treatment of GERD with symptoms or with esophageal injury is based on the suppression of acid secretion, particularly with proton pump inhibitors. When the hyperreactivity of the lower airways coexists with esophageal GERD symptoms, suppression of acid secretions should be of benefit in managing the respiratory disease in the presence of a causal relationship; however, this is not usual. When esophageal symptoms are not present, esophageal 24-hour pH study should be carried out prior to starting pharmacological treatment for GERD. Improvement of respiratory symptoms may be delayed with relation to esophageal symptoms. It is common for GERD to recur and pharmacological treatment should be repeated or continued indefinitely, depending on clinical presentation of the disease. Conclusions:The strategies that have been proposed for the pharmacological treatment of GERD in children are primarily based on studies of case series or on studies with adults. There have been very few controlled and randomized studies in children. Undertaking a greater number of these studies might reinforce existing aspects or establish new aspects of management.J Pediatr (Rio J). 2006;82(5 Suppl):S133-45: Gastroesophageal reflux, child, drug therapy, esophagitis, respiratory tract diseases, asthma. The symptoms of GERD are less common than the symptoms of GER, but, even so, are very prevalent. A prevalence study reported weekly heartburn sensation and acid regurgitation in approximately 2% of children aged 3 to 9 years and in 5% to 8% of 10 to 17 year-olds. REVIEW ARTICLEHeartburn alone was identified in 17.8% of the children in the older age group. 7 In the Western world, the prevalence of GERD among adults has been estimated from 10% to 20%. 5The refluxate may be exclusively acidic or mixed with duodenum-gastric reflux. Acid reflux is easier to identify and consequently the pathophysiology, diagnosis and treatment are better known. The bile reflux is little understood, but it has been related to severe esophagitis. 8 The case of mixed reflux diagnosis is highly problematic, and is one of the limitations of pH studies. There are no specific clinical trials on mixed reflux in the literature. has not specified the classification by age group, and most of the definitions proposed are applicable to adult patients. Notwithstan...

show abstract

Erythromycin as a prokinetic agent in infants and children

Cited by 61 publications

References 58 publications

Treatment of gastroesophageal reflux disease

Treatment of gastroesophageal reflux disease

Effect of Erythromycin on Gastric Emptying Time of Low Birth Weight Babies

Tratamento da doença do refluxo gastroesofágico

Contact Info

Product

Resources

About